Introduction
Vision correction with contact lenses offers some advantages as compared to correction with spectacles, but has some negative effect on the eye, too. It has been reported that annually about 0.5% of individuals wearing soft contact lenses (SCL) give up wearing them due to SCL intolerance or discomfort, and 5.2-15% of such individuals develop corneal allergic, toxic, infectious and/or metabolic complications [1] [2] [3] [4] [5] [6] .
Tissue hypoxia and mechanical compression are considered the most important contact lens-related factors affecting the anterior eye structures. Wearing contact lenses for a long time may lead to abnormalities in eye-winking reflex, tear production, and precorneal tear film stability, which may result in corneal surface roughness. Hypoxia causes metabolic alterations in the corneal epithelium and stroma, whereas direct contact of the lens with the ocular surface may lead to alterations in corneal curvature. Chronic hypoxia of the ocular surface is a leading cause of metabolic alterations in vision correction with contact lenses [7] [8] [9] [10] [11] . In addition, corneal metabolic changes are largely mediated by the effect of SCL on the tear film [5] .
Normally, tears provide oxygen to the cornea and wash away carbon dioxide. A contact lens provides a barrier to appropriate delivery of oxygen to and removal of products of metabolism from the eye, with the corneal epithelial permeability for carbon dioxide being 7 times higher than that for oxygen. Therefore, a contact lens creates conditions for a change in corneal pH, and, thereby, for an alteration in corneal metabolism. As a result, a shift takes place from aerobic energy production (i.e., glycolysis) towards anaerobic energy production in the epithelium, with a substantial increase in lactic acid production per energy unit. The lactic acid produced becomes accumulated in the outer corneal stroma, and corneal osmolarity becomes higher than that of the surrounding tear film or aqueous humor, with ingress of water from both sides to found mostly during check-ups, but, if untreated, may progress to higher stages with the development of serious complications. We have proposed a method for treating neurotrophic keratoconjunctivitis with morpholiniummethyl-triazolyl-thioacetate (thiotriazolin) using various routes of administration.
Pre-treatment studies of biochemical profiles of tear fluid in long-term SCL wearers would improve our knowledge on the pathogenesis of ocular surface changes depending on lens-wearing periods, and the comparison of pre-treatment and post-treatment data would contribute to clarification of the nature and extent of influence exerted by the agent on the pathological changes.
The purpose of the study was to compare the efficacy of different routes of administration of morpholinium-methyltriazolyl-thioacetate (thiotriazolin) for neurotrophic keratoconjunctivitis in patients wearing silicone hydrogel contact lenses for different periods of time.
Materials and Methods
This study included 217 eyes of 112 patients with low or moderate myopia who were examined and treated at the Department of Corneal Microsurgery, Filatov Institute.
The spectacle group (or control group) comprised 65 eyes of 33 patients with low or moderate myopia corrected with spectacles (25 (75.8%) women and 8 (24.2%) men; age, 22 to 51 years; mean age, 29.8±0.9 years), with a mean refraction of -3.87±0.2 D, uncorrected visual acuity (UCVA) of 0.01 to 0.7 (mean UCVA, 0.24±0.03), and best-corrected visual acuity (BCVA) of 0.4 to 1.2 (mean BCVA, 0.88±0.03).
The contact lens (CL) group comprised 152 eyes of 79 patients (61 (77.2%) women and 18 (22.8%) men; mean age, 30.8±0.4 years) wearing contact lenses for low or moderate myopia for 1 to 41 years, with a mean refraction of -4.12±0.2 D (p=0.17), mean UCVA of 0.12±0.01 (p=0.0000), and mean BCVA of 0.86±0.02 (p=0.28).
Patients of the CL group were divided into three subgroups based on treatment regimen. Patients of subgroup 1 received topical antiseptic (boric acid 2%) 2 times daily, thiotriazolin 1% 4 times daily, preservativefree hyaluronic acid artificial tears (optinol 0.21%) 4-6 times daily, and 1 thiotriazolin tablet 2 times daily for 1 month. Patients of subgroup 2 received topical antiseptic (boric acid 2%) 2 times daily, thiotriazolin 1% 4 times daily, and preservative-free hyaluronic acid artificial tears (optinol 0.21%) 4-6 times daily for 2 weeks. In addition, they received a course of transorbital electrophoresis with thiotriazolin 1% (10 procedures daily). Patients of subgroup 3 received topical antiseptic (boric acid 2%) 2 times daily and preservative-free hyaluronic acid artificial tears (optinol 0.21%) 4-6 times daily for 1 month.
Patients of the CL group were also divided into three categories based on CL-wearing period (1 to 5 years; 6 to 10 years; and > 10 years).
Subgroups 1, 2 and 3 comprised 33 patients (62 eyes; 24 (72.7%) women and 9 (27.3%) men), 31 patients (62 eyes; 23 (74.2%) women and 8 (25.8%) men), and 15 the cornea resulting in a decrease in stromal tonus. The corneal saturation with water exceeds the capacity for water withdrawal of the corneal endothelial pump that lacks energy for effective performance under anaerobic metabolism conditions [12, 13] .
Brzheskiy et al, Nikolska, and Teriokhina et al were among the first developers of tear research methodologies. Brzheskiy et al (1985) developed a methodology to measure tear glucose level. Nikolska (1985) developed a technique to assess coagulation and fibrinolytic activity of tear fluid. Teriokhina et al (1988) developed a method to measure tear enzyme levels in an effort both to predict the course and the chance of recurrence and to assess the efficacy of treatment for herpetic keratitis. Numerous studies have been reported on tear biochemistry in various ocular disorders [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Tear fluid provides physiological protection for the cornea, provides optimal conditions for various biochemical processes (first of all, for gas exchange between the cornea and atmospheric air) at the corneal surface [21, 22] .
A balance between lipid peroxidation (LPO) and antioxidant systems plays an important role in achieving and maintaining adaptation of the body in general and any body structure in particular [13, 19, 20, 23] .
Lipid peroxidation is a non-specific process, a lipid response to any stress during cell adaptation to the effect of negative factors [18, 20, 24] . It has been found that activation of LPO results in alteration in the phospholipid content of cell membranes. Elevated lipid peroxidation activity impedes microcirculation and nerve receptor function. In addition, it alters (a) nerve receptor sensitivity to hormones, mediators and immune parameters, and (b) adaptive capacity of cells. The final effect of LPO on tissues, cells and subcellular structures, and the degree of free radical-mediated tissue damage depend on the state of the antioxidant system [16] . Wearing SCL even for two hours causes a shift towards anaerobic metabolism in the cornea, which is evidenced by elevated activity of lactate dehydrogenase (LDH) in the tear film and hypoxic corneal swelling due to enzymatic dysfunction of the endothelial pumps [13] .
Biochemical studies of tear film are important in diagnosing various ocular disorders, predicting their course, and assessing the efficacy of therapeutic treatment for them [14] [15] [16] [17] There was no significant difference in CL-wearing period among the subgroups (F=0.54; p=0.58). In patients of subgroups 1, 2 and 3, mean CL-wearing period was 10.5±1.0 years (1 to 5 years, 20 (32.3%) eyes; 6 to 10 years, 18 (29%) eyes, > 10 years, 24 (38.7%) eyes), 10.5±0.9 years (1 to 5 years, 18 (29%) eyes; 6 to 10 years, 18 (29%) eyes, > 10 years, 26 (42%) eyes), and 8.9±0.9 years (1 to 5 years, 8 (28.6 %) eyes; 6 to 10 years, 11 (39.3%) eyes, > 10 years, 9 (32.1%) eyes), respectively.
Pre-and post-treatment tear samples were collected on filter paper strips and these strips were placed into an eppendorf tube. Tear activities of LDH, glucose-6-phosphate dehydrogenase (G6PDH), succine dehydrogenase (SDH), and acid phosphatase (AP), and tear contents of reduced and oxidized glutathione, and lipid peroxidation products (malondialdehyde and diene conjugates) were determined [29] .
Statistical analyses were conducted using Statistica 10.0 (StatSoft, Tulsa, OK, USA) software [12, 30] . Table 1 presents the findings regarding tear activities of LDH and G6PDH in low or moderate myopes wearing either spectacles (control group) or SCL for up to 5 years and treated with different treatment regimens (SCL group).
Results and Discussion
After treatment, tear activities of LDH in myopes wearing SCL for up to 5 years and treated in subgroups 1, 2 and 3, decreased by 22.2% (almost to the norm), 23.8% (almost to the norm) and 4.9% respectively. There were no statistically significant differences in post-treatment tear activities of LDH between subgroups 1 and 2, but, relative to patients of subgroup 3, post-treatment tear activities of LDH among patients of subgroup 1 and among patients of subgroup 2 were statistically significantly lower.
After treatment, tear activities of G6PDH in myopes wearing SCL for up to 5 years and treated in subgroups 1, 2 and 3, decreased by 20.8%, 19.2% and 2.9% (with no significant difference), respectively. There were no statistically significant differences in post-treatment tear activities of G6PDH between the subgroups. Table 2 presents the findings regarding tear activities of LDH and G6PDH in low or moderate myopes wearing either spectacles (control group) or SCL for 6 to 10 years and treated with different treatment regimens (SCL group).
After treatment, tear activities of LDH in myopes wearing SCL for 6 to 10 years and treated in subgroups 1, 2 and 3, decreased by 25%, 30.5% and 6.2% (with no significant difference), respectively. In addition, there were no statistically significant differences in post-treatment tear activities of the enzyme between subgroups 1 and 2. Moreover, post-treatment tear activities of the enzyme among patients of subgroup 1 and among those of subgroup 2 were not significantly different from the normal range.
After treatment, tear activities of G6PDH in myopes wearing SCL for 6 to 10 years and treated in subgroups 1, 2 and 3, decreased by 22.2%, 23% and 5.7% (with no significant difference), respectively. In addition, posttreatment tear activities of the enzyme among patients of subgroup 1 and among those of subgroup 2 were not significantly different from the normal range. Table 3 presents the findings regarding tear activities of LDH and G6PDH in low or moderate myopes wearing either spectacles (control group) or SCL for > 10 years and treated with different treatment regimens (SCL group). After treatment, tear activities of LDH in myopes wearing SCL for >10 years and treated in subgroups 1, 2 and 3, decreased by 31.4%, 34.8% and 5.8% (with no significant difference), respectively. In addition, there were no statistically significant differences in post-treatment tear activities of the enzyme between subgroups 1 and 2, but, relative to patients of subgroup 3, post-treatment tear activities of the enzyme among patients of subgroup 1 and among patients of subgroup 2 were statistically significantly lower.
After treatment, tear activities of G6PDH in myopes wearing SCL for >10 years and treated in subgroups 1, 2 and 3, decreased by 27.9%, 33.1% and 7.5% (with no significant difference), respectively. In addition, there were no statistically significant differences in posttreatment tear activities of the enzyme between subgroups 1 and 2. Moreover, post-treatment tear activities of the enzyme among patients of subgroup 1 and among those of subgroup 2 were not significantly different from the normal range.
Tear activities of LDH and G6PDH reflect a degree of epithelial destruction, since these enzymes are located in the cytoplasm of epithelial cells. The finding of elevated tear activities of these two enzymes provided the evidence for contact lens-induced intensive destruction of corneal cells and subcellular structures. The data provided in Tables 1 to 3 demonstrate that there is a direct relationship between duration of SCL wear and activities of these enzymes in the tear fluid, which suggests increased destruction of ocular surface cells. In addition, thiotriazolin was found to improve these parameters irrespective of its route of administration. Although the treatment regimen including electrophoresis with thiotriazolin was found to decrease tear activities of LDH and G6PDH to a somewhat greater extent than other regimens, this improvement was not statistically significant. Table 4 presents the findings regarding tear activities of SDH and AP in low or moderate myopes wearing either spectacles (control group) or SCL for up to 5 years and treated with different treatment regimens (SCL group). At baseline, tear SDH and AP levels were found to be elevated in SCL wearers, and to depend on duration of SCL wear (Table 4) . After treatment, tear activities of SDH in myopes wearing SCL for < 5 years and treated in subgroups 1, 2 and 3, decreased by 10.5%, 12.1% and 3.2% (with no significant difference), respectively. There were no statistically significant differences in posttreatment tear activities of the enzyme between subgroups 1, 2 and 3.
After treatment, tear activities of AP in myopes wearing SCL for <5 years and treated in subgroups 1 and 2, decreased by 10.5% and 15.1%, respectively, but subgroup 3 showed no decrease in this parameter. Post-treatment tear activities of AP among patients of subgroups 1 and 2 were not statistically significantly different from those among patients of subgroup 3. Table 5 presents the findings regarding tear activities of SDH and AP in low or moderate myopes wearing either spectacles (control group) or SCL for 6 to 10 years and treated with different treatment regimens (SCL group). After treatment, in myopes wearing SCL for 6 to 10 years and treated in subgroups 1, 2 and 3, tear activities of the former enzyme decreased by 13%, 16.8% and 2% (with no significant difference), respectively, and those of the latter anzyme decreased by 20.6%, 21.6% and 1.7% (with no significant difference), respectively. Table 6 presents the findings regarding tear activities of SDH and AP in low or moderate myopes wearing either spectacles (control group) or SCL for >10 years and treated with different treatment regimens (SCL group). After treatment, in myopes wearing SCL for >10 years and treated in subgroups 1, 2 and 3, tear activities of the former enzyme decreased by 18.4%, decreased by 23.1%, and did not decrease, respectively, and those of the latter anzyme decreased by 22.8%, 28.1% and 2.8% (with no significant difference), respectively. In addition, after treatment, for any duration of SCL wear, (a) there were no statistically significant differences in tear activities of SDH and AP between subgroups 1 and 2, and (b) these activities among patients of both subgroups were close to the normal range. Table 7 presents the findings regarding tear contents of reduced and oxidized glutathione in low or moderate myopes wearing either spectacles (control group) or SCL for <5 years and treated with different treatment regimens (SCL group). We found that, in any subgroup of the SCL group, pre-treatment tear contents of reduced and oxidized glutathione were diminished and elevated, respectively, indicating low antioxidant capacity in the anterior eye. Thiol system imbalance results in a reduced defensiveand-adaptive capacity of the cornea and other anterior eye structures in individuals wearing contact lenses for a long time.
After treatment, in myopes wearing SCL for <5 years and treated in subgroups 1, 2 and 3, tear contents of reduced glutathione increased by 15.4%, increased by 20.8%, and did not change significantly, respectively, whereas tear contents of oxidized glutathione decreased by 15.4%, decreased by 20.8%, and did not change significantly, respectively. Table 8 presents the findings regarding tear contents of reduced and oxidized glutathione in low or moderate myopes wearing either spectacles (control group) or SCL for 6 to 10 years and treated with different treatment regimens (SCL group). After treatment, in myopes wearing SCL for 6 to 10 years and treated in subgroups 1, 2 and 3, tear contents of reduced glutathione increased by 25.7%, increased by 26.5%, and did not change significantly, respectively, whereas tear contents of oxidized glutathione decreased by 16.0%, decreased by 15.9%, and did not change significantly, respectively. Table 9 presents the findings regarding tear contents of reduced and oxidized glutathione in low or moderate myopes wearing either spectacles (control group) or SCL for >10 years and treated with different treatment regimens (SCL group). After treatment, in myopes wearing SCL for >10 years and treated in subgroups 1, 2 and 3, tear contents of reduced glutathione increased by 30.5%, 35.8%, and 3.2% (an increase in subgroup 3 was not statistically significant), respectively, whereas tear contents of oxidized glutathione decreased by 14.0%, decreased by 18.1%, and did not change significantly, respectively. With regard to post-treatment tear contents of reduced and oxidized glutathione, there were no statistically significant differences between subgroups 1 and 2 for any CL-wearing period, and parameters among patients of both these subgroups were close to those of patients of the spectacle group. Table 10 presents the findings regarding tear contents of LPO products in low or moderate myopes wearing either spectacles (control group) or SCL for <5 years and treated with different treatment regimens (SCL group). After treatment, in myopes wearing SCL for <5 years and treated in subgroups 1 and 2, tear content of malondialdehyde (MDA) decreased by 15.4% and 18.1%, respectively, and that of diene conjugates decreased by 9.1% and 11.1%, respectively, while both these parameters did not change significantly in subgroup 3. With regard to post-treatment tear contents of MDA and diene conjugates, there were no statistically significant differences between subgroups 1 and 2. Table 11 presents the findings regarding tear contents of LPO products in low or moderate myopes wearing either spectacles (control group) or SCL for 6 to 10 years and treated with different treatment regimens (SCL group). After treatment, in myopes wearing SCL for 6 to 10 years and treated in subgroups 1 and 2, tear content of MDA decreased by 22.6% and 26.3%, respectively, and that of diene conjugates decreased by 12.1% and 11.4%, respectively. In addition, these parameters decreased by 2-3% in subgroup 3, although not statistically significantly. Table 12 presents the findings regarding tear contents of LPO products in low or moderate myopes wearing either spectacles (control group) or SCL for >10 years and treated with different treatment regimens (SCL group).
After treatment, in myopes wearing SCL for >10 years and treated in subgroups 1 and 2, tear content of MDA decreased by 25.2% and 29.9%, respectively, and that of diene conjugates decreased by 11.9% and 19.7%, respectively. In addition, these parameters decreased by 3.2% in subgroup 3, although not statistically significantly.
Conclusion
Activation of free radical processes and reduced antioxidative reserves lead to disruption of cellular and subcellular membranes of ocular surface epithelial cells (including, in particular, corneal epithelial cells) and play a crucial role in the pathogenesis of neurotrophic keratoconjunctivitis in individuals wearing soft contact lenses for years.
In patients wearing SCL for different time periods, our one-month multi-component therapy regimen 1 including topical and oral morpholinium-methyl-triazolyl-thioacetate (thiotriazolin) resulted in decreases in tear LDH, G6PDH, SDH and AP levels by 22-31%, 19-28%, 10-18%, and 10-23%, respectively. In addition, it resulted in increases in tear contents of reduced and oxidized glutathione by 15-30% and 12-14%, respectively, and decreases in tear contents of secondary LPO product (malondialdehyde) and primary LPO products (diene conjugates) by 15-25% and 9-12%, respectively.
Our two-week multi-component therapy (regimen 2) including topical thiotriazolin and electrophoresis using thiotriazolin decreased tear LDH, G6PDH, SDH and AP levels by 24-35%, 19-33%, 12-23%, and 15-28%, respectively. In addition, it increased tear contents of reduced and oxidized glutathione by 21-36% and 12-18%, respectively, and decreased tear contents of malondialdehyde and diene conjugates by 18-30% and 11-20%, respectively.
No statistically significant changes in the investigated parameters were found in myopes wearing SCL for different time periods and treated with topical antiseptic and hyaluronic acid artificial tears only, without adjunctive thiotriazolin (regimen 3). No statistically significant differences in treatment results between subgroups 1 and 2 were found, although in subgroup 2, the results were somewhat better, and the treatment course was shorter.
The use of thiotriazolin in the treatment of neurotrophic keratoconjunctivitis in individuals wearing SCL for years resulted in a statistically significant decrease in membrane lipid peroxidation activity due to restoration of prooxidative-antioxidative status, thus leading to stabilization of cell membranes and subcellular structures (organelles) of the ocular surface, in particular the cornea. Therefore, it was proved that thiotriazolin protects the ocular surface from oxidative stress. All of these point to the efficacy of pathogenetic treatment with thiotriazolin for neurotrophic keratoconjunctivitis in wearers of SCL for long periods, and to the potential for prevention of severe complications of vision correction with SCL. Table 5 . Tear activities of succine dehydrogenase (SDH) and acid phosphatase (AP) in patients wearing spectacles (control group) versus those wearing soft contact lenses (SCL) for 6 to 10 years and treated in treatment regimen subgroups 1, 2 or 3 (SCL group)
Note. n, number of eyes; p, significance of difference in parameter between the subgroup and the control group; p 1 , significance of difference between post-treatment and pre-treatment values; p 2 , significance of post-treatment difference in parameter between subgroup 1 (or subgroup 2) and subgroup 3; p 3 , significance of post-treatment difference in parameter between subgroup 2 and subgroup 3 Note. n, number of eyes; p, significance of difference in parameter between the subgroup and the control group; p 1 , significance of difference between post-treatment and pre-treatment values; p 2 , significance of post-treatment difference in parameter between subgroup 1 (or subgroup 2) and subgroup 3; p3, significance of post-treatment difference in parameter between subgroup 2 and subgroup 3 
